Monitoring Schistosome Hybrids Under Under Praziquantel Pressure (Sen_hybrids)

Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal

The overall objective of this project is to examine and quantify the potential existence and impact on Praziquantel (PZQ) efficacy, of naturally occurring S. haematobium and S. bovis hybrid populations in northern Senegal. Schistosome hybrids may present vigor compared to their pure parental forms and hence, may be less sensitive to PZQ. We hypothesise that PZQ repeated treatment selects the hybrid schistosome populations.

Study Overview

• Status: Unknown
• Conditions: Schistosomiasis
• Intervention / Treatment: Drug: Praziquantel 600 milligram

Detailed Description

Human schistosomiasis is a Neglected Tropical Disease caused by schistosome helminth worms with impressive epidemiological statistics associated: 800 million people at risk in 78 countries, > 230 million infected and > 200 000 deaths each year. The disease is highly endemic in sub-Saharan Africa where it persists despite mass drug administration with Praziquantel (PZQ). Some schistosomes are specific to humans and induce two main disease forms (either mesenteric or uro-genital) while others are associated with wild animals. However, hybridization can occur between different schistosome species. In northern Senegal, hybridization between schistosome species specific to humans and animals is now known to be frequent with the potential risk of zoonotic transmission.

This study will propose an integrative approach by conducting parasitological and molecular analysis including, schistosome miracidia genotyping to show if PZQ repeated treatment affects the genomic composition (Frequencies of alleles) of hybrid populations.

The objectives are:

• Determine the current prevalence of potential hybrid schistosome populations in their natural setting in Senegal
• Determine the sensitivity of hybrid schistosomes to praziquantel treatment in field populations
• Determine the molecular basis (at the genome level) of such phenotypic changes).

The study is a longitudinal observation of a cohort of school children after repeated Praziquantel (40 mg/kg) treatment, a drug commonly used through Mass Drug Administration (MDA) to treat schistosomiasis.

The cohort will be followed over a period of three years. Before the followup, a baseline urogenital schistosomiasis test will be performed on 1, 450 school-age children randomly selected in the five sites (290 in each site). All positive children will receive a single treatment (T1) of Praziquantel (PZQ) (40 mg/kg). Among those who test positive for S. haematobium eggs, only 50 in each site (five sites), who meet all the eligibility criteria will be invited to participate to the longitudinal follow-up. Four rounds of a single praziquantel (PZQ) treatment will be administered to positive individuals every 6 months. One round will consist of one treatment (T1 to T4) followed by a control treatment after one month (CT1 to CT4), hence, before the potential re-infecting schistosomes become adults and start egg-laying, which could bias the effectiveness of treatment evaluations. At each CT time, samples will be collected and S. haematobium eggs quantified (number of excreted eggs/10 mls of urine). Parasites (miracidia hatched from excreted eggs) will be recovered before each initial treatment (T1 to T4) and at CT1 to CT4 for subsequent genetic analysis to characterize hybrid schistosomes between S. haematobium and S. bovis.

• Study Type: Observational
• Enrollment (Anticipated): 250

Contacts and Locations

Study Locations

• Senegal
  • Dakar, Senegal, 18524
    • Recruiting
    • Bruno SENGHOR
    • Contact: Bruno SENGHOR, PhD; Phone Number: 776173437; Email: bruno.senghor@ird.fr
    • Contact: Cheikh Sokhna; Email: cheikh.sokhna@ird.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 years to 10 years (CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Northern Senegal Children

Description

Inclusion Criteria:

• Children between the initiation courses (CI) and elementary course second year (CE2)
• Absence of declared chronic pathologies that could impact the follow-up
• Be positive for S. haematobium infection during the selection period (excreting eggs)
• Residing in the study area during the 3 years of the follow-up

Exclusion Criteria:

• Absence of written informed consent or expressed refusal from the child
• Enrolled in another on going study, which implicates the administration of PZQ or tests another product.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in prevalence and intensity of schistosome infection	Determine at the 1 month post treatment the cure rate (CR) of the treatments and Egg Reduction Rates (ERR).	December 31. 2020

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hybrids tolerance to praziquantel	The frequency of hybrids and the level of genomic introgression between S. bovis and S. haematobium	December 31, 2021

Collaborators and Investigators

• Sponsor: Institut de Recherche pour le Developpement

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 11, 2020
• Primary Completion (ANTICIPATED): July 31, 2021
• Study Completion (ANTICIPATED): December 31, 2022

Study Registration Dates

• First Submitted: November 13, 2020
• First Submitted That Met QC Criteria: November 13, 2020
• First Posted (ACTUAL): November 19, 2020

Study Record Updates

• Last Update Posted (ACTUAL): November 19, 2020
• Last Update Submitted That Met QC Criteria: November 13, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Vector Borne Diseases; Parasitic Diseases; Helminthiasis; Trematode Infections; Schistosomiasis; Anti-Infective Agents; Antiparasitic Agents; Anthelmintics; Praziquantel
• Other Study ID Numbers: SEN2020-BS

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No